An 8-year-old child with acute myeloid leukemia (AML), underwent an allogeneic bone marrow transplant (BMT) from his HLA matched sister in spite of having a mild cardiomyopathy. We followed the patient with periodic electrocardiograms (ECG) and echocardiograms which have not worsened, and the patient's quality of life is not compromised 14 years after BMT. Bone Marrow Transplantation (2000) 25, 335-336. Keywords: acute myeloid leukemia; anthracyclines; bone marrow transplantation; cardiomyopathy; total body irradiation Eligibility criteria for bone marrow transplantation (BMT) usually include the absence of cardiac abnormalities. Highdose cyclophosphamide and total body irradiation (TBI) used as conditioning for BMT can be associated with acute cardiac toxicity ranging from an asymptomatic pericardial effusion and reduction in electrocardiographic voltage (ECG) resulting in myopericarditis to congestive heart failure, which can be fatal. [1] [2] [3] Longitudinal studies of cardiac function post-BMT in children have rarely been carried out, and few data are available on patients surviving more than 1 year after BMT. 4 We report a child, treated for acute non-lymphoblastic leukemia, by BMT performed despite mild cardiac dysfunction. After 14 years of follow-up the heart impairment is still mild and the patient's quality of life is not significantly impaired, permitting a normal social and working life.
Eligibility criteria for bone marrow transplantation (BMT) usually include the absence of cardiac abnormalities. Highdose cyclophosphamide and total body irradiation (TBI) used as conditioning for BMT can be associated with acute cardiac toxicity ranging from an asymptomatic pericardial effusion and reduction in electrocardiographic voltage (ECG) resulting in myopericarditis to congestive heart failure, which can be fatal. [1] [2] [3] Longitudinal studies of cardiac function post-BMT in children have rarely been carried out, and few data are available on patients surviving more than 1 year after BMT. 4 We report a child, treated for acute non-lymphoblastic leukemia, by BMT performed despite mild cardiac dysfunction. After 14 years of follow-up the heart impairment is still mild and the patient's quality of life is not significantly impaired, permitting a normal social and working life.
Case report
An 8-year-old boy was diagnosed with acute nonlymphoblastic leukemia (FAB-M4) in February 1984. Induction therapy consisted of two courses of continuous infusion cytarabine (100 mg/m 2 /day for 7 days) and rapid Four months later, the boy underwent allogeneic BMT from his HLA A, B and DR matched sister. At the pre-BMT evaluation, the mono-dimensionally guided M-MODE echocardiogram showed a mild hypokinesis of the interventricular septum, with a left ventricular function index at the lower limit of normal (shortened fraction = 29%). Despite this mild cardiac impairment, the inherent risk of heart damage was considered acceptable and BMT was performed. Conditioning was with cyclophosphamide (60 mg/kg/day for 2 days) and TBI (10 Gy in a single dose). Graft-versus-host disease (GVHD) prophylaxis included methotrexate (MTX) 15 mg/m 2 i.v. on day +1, MTX 10 mg/m 2 i.v. on days +3, +6, +11 and cyclosporine (CYA) at standard dosage. Marrow engraftment occurred for neutrophils and platelets at days +15 and +50, respectively. Acute GVHD involving the skin and mucosa, did not occur. Chronic skin GVHD, which developed 'de novo' in the fourth month post-BMT, was treated with steroids and CyA at standard doses for 4 years.
After BMT the patient underwent cardiological checkups (ECG and mono-dimensionally guided M-MODE echocardiogram) every 4 months.
Twenty months after BMT, an increase in blood pressure (120/100 mmHg), probably due to the combined administration of CYA and steroids, was treated with nifedipine (1 mg/kg/day) and propranolol (1 mg/kg/day) for 2 months, then with furosemide (0.5 mg/kg/day) for 15 months.
Echocardiograms performed regularly during follow-up did not reveal significant changes. Twelve years after BMT, the patient was symptomatic, with mild dyspnoea and arterial hypertension; a 2-dimensionally guided M-MODE echocardiogram showed hypokinetic cardiomyopathy with dysfunctional left ventricular contraction and slight left ventricle failure (shortened fraction = 24%). Therapy with an ACE inhibitor (Enalapril 20 mg/day) and digoxin (0.250 mg/day) was started. This episode occurred at the same time as a transient upper respiratory tract viral infection. One month after this episode, another two-dimensionally guided M-MODE echocardiogram demonstrated a modest degree of hypokinesis with cardiac compensation from ther-apy with the ACE inhibitor and digitalis, which are still being administered.
Today, the boy has a Karnofsky score of 90% and works part-time. Mild and limited chronic skin and conjunctival GVHD is still present and treated with topical and symptomatic therapy only. Annual respiratory check-ups (spirometers) show an asymptomatic restrictive pattern. A final routine two-dimensionally guided M-MODE echocardiogram carried out in February 1999, reconfirmed diffuse hypokinesis with a systolic functional index slightly lower than normal (shortened fraction = 26%).
Discussion
In spite of receiving a pre-transplant cumulative anthracycline dose of only 270 mg/m 2 , our patient developed a modest, asymptomatic cardiomyopathy. However, this did not contraindicate BMT which was the most suitable therapy available for his disease at that time. Frequent cardiac monitoring has allowed us to confirm that no substantial changes have occurred after BMT. The patient's general condition and quality of life are quite good 14 years on, despite the continued presence of subclinical damage.
Induction therapy for AML primarily included anthracyclines which are known to be potentially cardiotoxic. Lipshultz et al recently described that the higher the dose of anthracyclines the greater the risk of cardiotoxicity, even though the dosage likely to cause toxic damage is extremely variable and depends on age, gender and other patient characteristics. 6 The ejection-phase indices of left ventricular systolic function (including shortening fraction, ejection fraction, and velocity of fiber shortening) can detect acute declines in ventricular function associated with anthracycline administration and may help to provide an insight into the nature of their late effects. 6 The frequency of clinically apparent toxicity increases as the cumulative dose of anthracyclines approaches 450 mg/m 2 ; attempts to prevent congestive heart failure include dose limitation and regular evaluation by one or more noninvasive methods such as ECG (15% of patients had an abnormally prolonged QT c interval), echocardiogram (10% had an abnormally low shortening fraction). Shortening fraction (SF) is the most universally accepted measurement of systolic function and is widely used to screen for myocardial dysfunction. 7 In children with AML, who are candidates for BMT, the early cardiotoxic effects of the conditioning regimen (in particular TBI and Cy) must be added to that of anthracyclines previously administered. 1, 2 However, longitudinal studies of cardiac function post-BMT in children, have rarely been carried out and little data are available on patients surviving more than 1 year after BMT. 4, 8 We studied late cardiac function changes in 51 children undergoing BMT for hematological malignancies between 1987 and 1991, with a median follow-up of 5 years. 9 No child in our series complained of symptoms attributable to heart dysfunction at any time during the post-BMT follow-up. Nevertheless, some children had evidence of a slight decrease in cardiac function before BMT (SF = 33.5% ± 3.7) due to cardiotoxic therapy received as part of their conventional anti-leukemic treatment (including anthracylines). 9 In summary, we would emphasize the importance of carrying out a full pre-BMT evaluation, particulary with regard to cardiac function and possible anthracycline damage, relating this to the risk-benefits associated with the transplant procedure.
In our patient, mild pre-BMT cardiomyopathy was not a contraindication for allogeneic BMT, which allowed us to cure the underlying AML without significant worsening of cardiologic status in the long term.
The mild hypokinetic left ventricle cardiomyopathy could have been due to myocardial fibrosis and the consequent anthracycline therapy, TBI and chronic GVHD.
